



"Value for money in oncology research"

28th Annual Scientific Meeting

14 – 17 March 2016

Brisbane Convention & Exhibition Centre

*Please note this is a Preliminary Program and is subject to changes.
Updates will be made as topics, presentations and presenters are confirmed.*

8.30am – 10.30am		Opening Session	Boulevard Auditorium
8.30 – 8.35am		Convenor Welcome	
8.35 – 8.40am		Welcome to Country	
8.40 – 8.55am		Official Welcome	
8.55 – 9.10am		President's Report	
9.10 – 9.20am		TSC Update	
9.20 – 9.40am		TCOO Update	
9.40 – 10.10am		International Guest Speaker: Dr Tito Fojo M.D., Ph.D. "The Current Oncology Fantasy: Personalised/Precision Medicine"	
10.10 – 10.30am		National Guest Speaker: Professor Marion Haas "Health Economics 101"	
10.30 – 11.00am		Boulevard Foyer	Morning Tea
11.00am – 1.00pm		Breast SubSpecialty Group Session	Boulevard - B1
Chair: Peter Graham			
11.00 - 11.05am		Welcome	
11.05 – 11.25am		National Guest Speaker: Dr Nicole Haynes "Harnessing the therapeutic potential of radiation therapy with antibody-based immunotherapeutic strategies"	
11.25 – 11.45am		New trial proposal presentation – Category B Randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterized low-risk luminal A early breast cancer	
11.45 – 11.55am		Local HER-0: A phase II pilot study of local therapy only (stereotactic radiosurgery and or surgery) for treatment of up to 5 brain metastases from HER2+ breast cancer.	
11.55am - 12.05pm		HART: Deep Inhalation Breath Hold radiotherapy for patients with left sided breast cancer.	
12.05 – 12.10pm		08.06 (STARS): A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy.	

12.10 – 12.15pm	12.02 (PET-LABRADOR): Pet scans for Locally Advanced Breast cancer and diagnostic MRI to determine the extent of Operation and Radiotherapy.
12.15 – 12.20pm	07.01 (DCIS): A randomised phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast.
12.20 – 12.25pm	11.01 (SUPREMO): A phase III randomised trial to assess the role of adjuvant chest wall irradiation in 'intermediate risk' operable breast cancer following mastectomy. SUPREMO (Selective Use of Postoperative Radiotherapy after Mastectomy) BIG 2-04
12.25 – 12.30pm	06.02 (APBI): A Multicentre Feasibility Study of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal Radiation Therapy for Early Breast.
12.30 – 12.35pm	10.02 (RAPID): Randomized trial of accelerated partial breast irradiation.
12.35 – 1.00pm	Discussion

11.00am – 1.00pm

Genito-Urinary SubSpecialty Group Session

Boulevard - B2

Co-Chairs: David Pryor / Shankar Siva

11.00 – 11.05am	Welcome
11.05 – 11.25am	New trial proposal: FASTRACK II (Category A) Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial.
11.25 – 11.45am	CORE: A multistage multicentre international randomised trial of Conventional care Or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease (CORE) in lung, breast and prostate cancer.
11.45am– 12.05pm	New trial proposal: PopstAR-N (Category B) PSMA-PET directed Oligometastatic Prostate cancer treated with Stereotactic Ablative Radiotherapy to Nodes.
12.05 – 12.15pm	14.02 (RAIDER): A randomised phase II trial of adaptive image guided standard or dose escalated radiotherapy in the treatment of transitional cell carcinoma of the bladder.
12.15 – 12.25pm	15.01 (SPARK): Stereotactic Prostate Adaptive Radiotherapy utilising KIM (Kilovoltage Intrafraction Monitoring).
12.25 – 12.35pm	14.01 / ANZUP1303 (ENZARAD): Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer.
12.35 – 12.45pm	08.03 (RAVES): A phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with early salvage RT in patients with positive margins or extraprostatic disease following radical prostatectomy.
12.45 – 1.00pm	Discussion

11.00am – 1.00pm

Head & Neck and Skin SubSpecialty Groups Session

Boulevard Auditorium

Co-Chairs: Chris Wratten 11am – 12.15pm

June Corry 12.25pm – 1pm

11.00 – 11.05am	Welcome
-----------------	---------

11.05 – 11.55am	National Guest Speaker: Professor Peter Hersey “Challenges for radiotherapy in the anti PD1/PD-L1 era”
11.55am – 12.05pm	09.03 (MP3): A phase II efficacy study of chemo-radiotherapy in PET stage II and III Merkel cell carcinoma of the skin.
12.05 – 12.15pm	08.09 (RTN2): A randomised trial of post operative radiation therapy following wide excision of neurotropic melanoma of the head and neck.
12.15 – 12.25pm	08.05 (WBRT): Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma-A randomised phase III trial.
12.25 – 12.35pm	05.01 (POST): Post operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
12.35 – 12.45pm	14.03 (EORTC1219): A blind randomized multicentre study of accelerated fractionated chemo-radiotherapy with or without the hypoxic cell radiosensitizer nimorazole (Nimoral), using a 15-gene signature for hypoxia in the treatment of HPV/p16 negative squamous cell carcinoma of the head and neck.
12.45 – 12.55pm	12.03 (EAT): Eating As Treatment (EAT): An RCT of psychological training for dieticians to reduce malnutrition and depression in head and neck cancer patients undergoing radiotherapy.
12.55 – 1.00pm	12.01 (HPV Oropharynx): A randomised trial of weekly cetuximab and radiation versus weekly cisplatin and radiation in good prognosis locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma.
11.00am – 1.00pm Lung SubSpecialty Group Session Boulevard – B3	
Chair: Fiona Hegi Johnson	
11.00 – 11.05am	Welcome
11.05 – 11.30am	International Guest Speaker: Professor Dirk De Ruyscher “Radiotherapy and immune therapy: Good partners?”
11.30 – 11.40am	SABR-OS: A phase II randomized trial to test the feasibility of randomizing patients with peripheral stage I non-small cell lung cancer (NSCLC) to either Stereotactic Ablative Radiotherapy (SABR) Or Surgery
11.40 – 11:50am	NivoRAD: Nivolumab vs nivolumab/RT in NSCLC: Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy.
11.50am –12.00pm	13.01 (SAFRON II): Stereotactic Ablative Fractionated Radiotherapy versus radiosurgery for Oligometastatic Neoplasia to the lung: A randomised Phase II trial.
12.00 – 12.10pm	11.03 (PLUNG_GP): Randomised Phase III trial of high dose palliative radiotherapy (HDPRT) vs Concurrent chemotherapy plus HDPRT (C-HDPRT) in good performance status patient with locally advanced or small volume metastatic NSCLC – not suitable for radical chemo-radiotherapy.
12.10 – 12.20pm	09.02 (CHISEL): A Randomised Phase III trial of highly conformal hypofractionated image guided (“stereotactic”) radiotherapy (hypoRT) versus conventionally fractionated radiotherapy (conRT) for inoperable early stage I non-small cell lung cancer.
12.20 – 12.40pm	National Guest Speaker: Associate Professor Nick Pavlakis “Targeted systemic therapies in lung cancer - relevance to radiotherapy”
12.40 – 1.00pm	Discussion: Horizon scanning / Holes in the portfolio

1.00 – 1.50pm		Lunch	Boulevard Foyer
2.00 – 2.50pm		Afternoon Breast SubSpecialty Group Session	Boulevard – B1
Chair: Boon Chua			
2.00 – 2.30pm	National Guest Speaker: Professor Sunil Lakhani “Review of established and emerging biomarkers in breast cancer”		
2.30 – 2.50pm	Discussion: Horizon scanning / New research directions, opportunities and challenges		
2.00 – 2.50pm		Afternoon Genito-Urinary SubSpecialty Group Session	Boulevard – B2
Co-Chairs: David Pryor / Shankar Siva			
2.00 – 2.15pm	National Guest Speaker: Paul Thomas “PSMA PET trials in prostate cancer and renal cell carcinoma”		
2.15 – 2.30pm	Translational collaborations – integrating tissue / serum biomarkers into GU studies		
2.30 – 2.50pm	Discussion: Horizon scanning		
2.00 – 2.50pm		Afternoon Head & Neck and Skin SubSpecialty Groups Session	Boulevard Auditorium
Chair: Chris Wratten			
2.00 – 2.50pm	Interactive session: • Horizon Scanning • Holes in the portfolio • Other Collaborations • Where to next		
2.00 – 2.50pm		Afternoon Lung SubSpecialty Group Session	Boulevard – B3
Chair: Fiona Hegi Johnson			
2.00 – 2.10pm	New Proposal: DESSERT (Category A) Decision Support Systems for Radiation Therapy in Non-Small Cell Lung Cancer.		
2.10 – 2.30pm	New trial proposals presentation – Category B (trials TBC)		
2.30 – 2.40pm	Discussion: New proposals – what to support?		
2.40 – 2.50pm	Discussion: Other collaborations		
2.50 – 3.10pm		Afternoon Tea	Boulevard Foyer

Boulevard Auditorium		Session Chair: Farshad Foroudi
3.10 – 3.25pm	03.05 (MA.20): A Phase III study of regional radiation therapy in early breast cancer.	
3.25 – 3.55pm	National Guest Speaker: Richard De Abreu Lourenço “Using health economics in radiotherapy research”	
3.55 – 4.05pm	RANZAR: Registry of Australian and New Zealand Ablative Radiotherapy	
4.05 – 4.15pm	15.02 (ROAM): Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial	
4.15 – 4.25pm	08.08 (TOPGEAR): A randomised Phase II/III trial of preoperative Chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.	
4.25 – 4.35pm	11.02 (SCORAD III): A Randomised Phase III study of single fraction radiotherapy compared to multi-fraction radiotherapy in patients with metastatic spinal cord compression.	
4.35 – 4.45pm	03.01 (Oesophagus (Dysphagia)): A randomised phase III study in advanced oesophageal carcinoma to compare dysphagia in patients treated with radiotherapy versus chemo-radiotherapy.	
4.45 – 4.55pm	04.02 (Cervical (FIGO Stage & Tumour Volume)): Prospective Study to Determine the Relationships Between Survival and FIGO Stage, Tumour Volume and Corpus Invasion in Cervical Cancer.	
4.55 – 5.00pm	06.01 Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study.	
7.00 – 10.00pm	Welcome Dinner - Sponsored by Brainlab	Gallery Of Modern Art - Roof Terrace

8.15 – 8.45am **Breakfast session - Sponsored by Varian** **Boulevard B1**

Boulevard Auditorium **New Proposals Session - Chair: David Christie**

9.00am – 9.10am	New Proposal: FASTRACK II (Category A) Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial.
9.10am – 9.20am	Discussant 10 mins
9.20am – 9.30am	New Proposal: DESSERT (Category A) Decision Support Systems for Radiation Therapy in Non-Small Cell Lung Cancer.
9.30am – 9.40am	Discussant 10 mins
9.40am – 9.45am	New Proposal: Review of (TBC) trial (Category B)
9.40am – 9.50am	New Proposal: A randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised low-risk luminal A early breast cancer (Category B)
9.50am – 10.00am	New Proposal: PLATO / ACT5 (Category B)
10.00am – 10.10am	ZEST
10.10am – 10.20am	DATA Mining
10.20am – 10.30am	Media slot

10.30 – 11.00am **Morning Tea** **Boulevard Foyer**

11.00 – 11.45am	International Guest Speaker: Dr Tito Fojo M.D., Ph.D. "Recurrent problems with the design and interpretation of oncology clinical trials"
-----------------	--

11.45am – 1.00pm **Annual General Meeting** **Boulevard Auditorium**

1.00pm – 1.30pm **Lunch** **Boulevard Foyer**

1.30pm – 4.30pm **Social Afternoon - Afternoon tea at the Convention Centre or the Botanical Gardens**

7.00pm – 11.00pm **Gala Dinner - Sponsored by Elekta** **Boulevard Room**

8.15 – 8.45am

Breakfast session - Sponsored by GenesisCare

Boulevard – B1

9.00am – 1.05pm

Boulevard Auditorium

Breast SubSpecialty Group Feedback Session - Chair: Verity Ahern

9.00 – 9.20am

Summary of the TROG portfolio of Breast Studies

9.20 – 9.30am

Summary of new trial proposals and recommendations of the group

9.30 – 9.45am

Strategic direction of the group

Genito-Urinary SubSpecialty Group Feedback Session - Co-Chairs: David Pryor / Shankar Siva

9.45 – 10.10am

GU Session Summary:

- New trial proposals
- In development
- Future directions

10.10 – 10.30am

03.06 (TOAD): A collaborative randomized phase III trial: The timing of intervention with androgen deprivation in prostate cancer patients with a rising PSA (Closed)
Update - Landmark results

10.30 – 11.00am

Morning Tea

Boulevard Foyer

Head & Neck and Skin SubSpecialty Groups Feedback Sessions

Co-Chairs: June Corry / Chris Wratten

11.00 – 11.20am

Head and Neck Session Summary:

- Issues with current trials
- Where to next

11.20 – 11.45am

Skin Session Summary:

- Issues with current trials
- Where to next

Lung SubSpecialty Group Feedback Session - Chair: Fiona Hegi Johnson

11.45am – 12.10pm

Lung Session Summary:

- new trial proposals and the group's recommendations
- Issues with current trials
- Where to next

12.10 – 12.30pm

International Guest Speaker: Prof Dirk De Ruyscher
"Individualized radiotherapy: How biology, physics and genetics meet"

Closing session

12.30 – 1.00pm

International Guest Speaker: Dr Tito Fojo
"A fair price for cancer drugs can be achieved but only if we resolve to make tough decisions"

1.00 – 1.05pm	Close of 2016 ASM – Introduction of 2017 ASM Convenor and venue
1.05pm – 1.30pm	Lunch Boulevard Foyer
1.30 – 3.30pm	TSC Meeting - by invitation only

PRELIMINARY PROGRAM